The purpose and effect of this rule development is to address self-administration of pancreatic enzyme medication by students diagnosed with pancreatic insufficiency or cystic fibrosis enrolled in the public school system.  


  • RULE NO.: RULE TITLE:
    6A-6.0252: Use of Prescribed Pancreatic Enzyme Supplements
    PURPOSE AND EFFECT: The purpose and effect of this rule development is to address self-administration of pancreatic enzyme medication by students diagnosed with pancreatic insufficiency or cystic fibrosis enrolled in the public school system.
    SUBJECT AREA TO BE ADDRESSED: The self-administration of pancreatic enzyme medication by students diagnosed with pancreatic insufficiency or cystic fibrosis.
    RULEMAKING AUTHORITY: 1002.20(3)(k) FS.
    LAW IMPLEMENTED: 1002.20(3)(k) FS.
    IF REQUESTED IN WRITING AND NOT DEEMED UNNECESSARY BY THE AGENCY HEAD, A RULE DEVELOPMENT WORKSHOP WILL BE HELD AT THE DATE, TIME AND PLACE SHOWN BELOW:
    DATE AND TIME: November 8, 2011, 9:00 a.m. until completion
    PLACE: Department of Education, Turlington Building, 325 West Gaines Street, Room 1701, Tallahassee, Florida 32399. Conference call 1(888)808-6959, When prompted, enter your Conference Code (6351196864) followed by #.
    THE PERSON TO BE CONTACTED REGARDING THE PROPOSED RULE DEVELOPMENT AND A COPY OF THE PRELIMINARY DRAFT, IF AVAILABLE, IS: Cathy Bishop, Interim Chief, Bureau of Exceptional Education and Student Services, K-12 Public Schools, Department of Education, 325 West Gaines Street, Room 614, Tallahassee, Florida 32399, (850)245-0475. To request a rule development workshop, please contact: Lynn Abbott, Agency Clerk, Department of Education, (850)245-9661 or e-mail lynn.abbott@fldoe.org or go to: https://app1.fldoe.org/rules/default.aspx

    THE PRELIMINARY TEXT OF THE PROPOSED RULE DEVELOPMENT IS:

    Available at: https://app1.fldoe.org/rules/default.aspx

Document Information

Subject:
The self-administration of pancreatic enzyme medication by students diagnosed with pancreatic insufficiency or cystic fibrosis.
Purpose:
The purpose and effect of this rule development is to address self-administration of pancreatic enzyme medication by students diagnosed with pancreatic insufficiency or cystic fibrosis enrolled in the public school system.
Rulemaking Authority:
1002.20(3)(k) FS.
Law:
1002.20(3)(k) FS.
Contact:
Cathy Bishop, Interim Chief, Bureau of Exceptional Education and Student Services, K-12 Public Schools, Department of Education, 325 West Gaines Street, Room 614, Tallahassee, Florida 32399, (850)245-0475. To request a rule development workshop, please contact: Lynn Abbott, Agency Clerk, Department of Education, (850)245-9661 or e-mail lynn.abbott@fldoe.org or go to: https://app1.fldoe.org/rules/default.aspx
Related Rules: (1)
6A-6.0252. Use of Prescribed Pancreatic Enzyme Supplements